Quick Answer
Vistagen Therapeutics, Inc. reported Operating Income of -$55.97 million for fiscal year 2025.
Vistagen Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$55.97M | -69.5% |
| 2024 | -$33.02M | +44.3% |
| 2023 | -$59.27M | -24.0% |
| 2022 | -$47.78M | -166.4% |
| 2021 | -$17.93M | +13.8% |
| 2020 | -$20.80M | +15.3% |
| 2019 | -$24.56M | -72.9% |
| 2018 | -$14.20M | -38.6% |
| 2017 | -$10.25M | +42.6% |
| 2016 | -$17.85M | -163.4% |
| 2015 | -$6.78M | -34.8% |
| 2014 | -$5.03M | +26.0% |
| 2013 | -$6.79M | +24.9% |
| 2012 | -$9.04M | -37.8% |
| 2011 | -$6.56M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$19.55M | -29.3% | +2.5% |
| September 30, 2025 | -$20.05M | -41.0% | -26.9% |
| June 30, 2025 | -$15.80M | -30.3% | -4.5% |
| December 31, 2024 | -$15.12M | -91.8% | -6.3% |
| September 30, 2024 | -$14.23M | -109.8% | -17.3% |
| June 30, 2024 | -$12.13M | -73.3% | -53.9% |
| December 31, 2023 | -$7.88M | +19.3% | -16.3% |
| September 30, 2023 | -$6.78M | +61.2% | +3.1% |
- Vistagen Therapeutics, Inc. showed a decrease of -69.5% in Operating Income compared to the prior fiscal year.
- Over the 2011–2025 period, Vistagen Therapeutics, Inc.’s operating income has declined by 752.6% (from -$6.56 million to -$55.97 million).
- The most recent figure is from Vistagen Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 17, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: